7 New Approved Drugs for Primary Care: Q3 2023

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

News

Slideshow

First nonprescription daily oral contraceptive pill, OTC opioid antagonist nasal spray for opioid overdose, and 5 more FDA-approved drugs primary care clinicians should know about.

US Food and Drug Administration (FDA) new drug approvals in the third quarter of 2023 include numerous “firsts,” such as the first over-the-counter daily oral contraceptive pill, the first vaccine against respiratory syncytial virus (RSV) in neonates and children up to 24 months of age, the first oral medication for postpartum depression, and more. Find details on these and 4 more in the slides below.

Related Content

January 17th 2025

Respiratory Tripledemic 2022-23: An Expert Recap

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

April 6th 2023

Novel Tool Predicts Onset Age of Cognitive Impairment and Alzheimer Dementia

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

January 16th 2025

Distress Signals: How to Help a Clinician Colleague in Need

The Florey Dementia Index showed robustness across different cohorts but more testing is needed, researchers reported.

February 14th 2023

USPSTF Issues Final Recommendations on Osteoporosis Screening to Prevent Fractures

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Rebekah Bernard, MD, a family physician and national speaker on physician wellness.

Elinzanetant VMS update: As Positive Results Pile Up, Bayer Readies for Menopause Treatment’s Future

The USPSTF recommends all women ages 65 and older and at-risk postmenopausal women under 65 should be screened for osteoporosis.

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

FDA action date set for July 26, 2025.

Related Content

January 17th 2025

Respiratory Tripledemic 2022-23: An Expert Recap

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

April 6th 2023

Novel Tool Predicts Onset Age of Cognitive Impairment and Alzheimer Dementia

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

January 16th 2025

Distress Signals: How to Help a Clinician Colleague in Need

The Florey Dementia Index showed robustness across different cohorts but more testing is needed, researchers reported.

February 14th 2023

USPSTF Issues Final Recommendations on Osteoporosis Screening to Prevent Fractures

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Rebekah Bernard, MD, a family physician and national speaker on physician wellness.

Elinzanetant VMS update: As Positive Results Pile Up, Bayer Readies for Menopause Treatment’s Future

The USPSTF recommends all women ages 65 and older and at-risk postmenopausal women under 65 should be screened for osteoporosis.